Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
Jai N. Patel(Levine Cancer Institute), Howard L. McLeod(Unknown), Janey Wang(Vanderbilt University Medical Center), Michael J. Morris(Dana-Farber Cancer Institute), Yoichi Furukawa(The University of Tokyo), Cameron Lassiter(University of Maryland, Baltimore), Kouros Owzar(Duke University), Michael J. Kelley(Durham VA Health Care System), Flora Mulkey(Sherwin Williams (United States)), Susan Halabi(Duke Medical Center), Mark J. Ratain(University of Chicago), Michiaki Kubo(RIKEN Center for Integrative Medical Sciences), Daniel L. Hertz(GTx (United States)), Susan G. Dorsey(University of Maryland, Baltimore), Chen Jiang, Yusuke Nakamura(National Institute of Biomedical Innovation, Health and Nutrition), William Kevin Kelly(Thomas Jefferson University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Paula N. Friedman(University of North Carolina at Chapel Hill), Eric J. Small(CancerCare Manitoba)
Cited by 1
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k